Piper Sandler Reiterates Its ‘Overweight’ Rating on AbbVie Inc. (ABBV) with a $231 PT

Group 1 - AbbVie Inc. is recognized as one of the 15 best stocks for financial stability and is rated 'Overweight' by Piper Sandler with a price target of $231 [1][2] - The company has reached a settlement with ANDA filers regarding Rinvoq, delaying generic entry until April 2037, which extends its exclusivity period [2][3] - This settlement is expected to enhance AbbVie's long-term earnings outlook, with projections indicating that Rinvoq could exceed $10 billion in annual U.S. sales by 2030 [3] Group 2 - AbbVie is a global biopharmaceutical company that develops and markets innovative medicines across various therapeutic areas, including immunology, oncology, and neuroscience [4]